Seoul Pharma Co. Ltd Total Liabilities
Seoul Pharma Co. Ltd total liabilities. Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has total liabilities worth ₩32.70 Billion KRW (≈ $22.16 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 018680 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Seoul Pharma Co. Ltd (2012–2024)
Total liabilities of Seoul Pharma Co. Ltd from 2012 to 2024. This chart illustrates how Seoul Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Seoul Pharma Co. Ltd (018680) long-term investment share to see how much of total assets are deployed in long-term investments.
Seoul Pharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Seoul Pharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quanome Technologies, Inc.
NASDAQ:QNME
|
USA | $4.65 Million |
|
Sebata Holdings Ltd
JSE:SEB
|
South Africa | ZAC369.87 Million |
|
Riley Gold Corp
V:RLYG
|
Canada | CA$310.02K |
|
ASIASOFT CORP.-NVDR-05
F:5ASA
|
Germany | €362.11 Million |
|
Biofrontera Inc
NASDAQ:BFRI
|
USA | $18.11 Million |
|
Research Frontiers Incorporated
NASDAQ:REFR
|
USA | $1.30 Million |
|
VAIV Co. Inc.
KQ:301300
|
Korea | ₩25.20 Billion |
|
Ozerden Plastik Sanayi
IS:OZRDN
|
Turkey | TL52.79 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Seoul Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Seoul Pharma Co. Ltd.
Liquidity & Leverage Metrics
Seoul Pharma Co. Ltd Total Liabilities Ratios Explained
Seoul Pharma Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seoul Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual total liabilities of Seoul Pharma Co. Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩31.45 Billion ≈ $21.31 Million |
+27.11% |
| 2023-12-31 | ₩24.74 Billion ≈ $16.77 Million |
-8.39% |
| 2022-12-31 | ₩27.01 Billion ≈ $18.30 Million |
-37.62% |
| 2021-12-31 | ₩43.29 Billion ≈ $29.34 Million |
+19.48% |
| 2020-12-31 | ₩36.23 Billion ≈ $24.56 Million |
-14.62% |
| 2019-12-31 | ₩42.44 Billion ≈ $28.76 Million |
+5.43% |
| 2018-12-31 | ₩40.25 Billion ≈ $27.28 Million |
+21.70% |
| 2017-12-31 | ₩33.08 Billion ≈ $22.42 Million |
-34.47% |
| 2016-12-31 | ₩50.47 Billion ≈ $34.20 Million |
+2.70% |
| 2015-12-31 | ₩49.15 Billion ≈ $33.31 Million |
+2.65% |
| 2014-12-31 | ₩47.88 Billion ≈ $32.45 Million |
+22.23% |
| 2013-12-31 | ₩39.17 Billion ≈ $26.55 Million |
+10.99% |
| 2012-12-31 | ₩35.29 Billion ≈ $23.92 Million |
-- |
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more